Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Adv Drug Deliv Rev ; 106(Pt A): 3-26, 2016 11 15.
Artigo em Inglês | MEDLINE | ID: mdl-27473931

RESUMO

Targeted delivery of nucleic acids into disease sites of human body has been attempted for decades, but both viral and non-viral vectors are yet to meet our expectations. Safety concerns and low delivery efficiency are the main limitations of viral and non-viral vectors, respectively. The structure of viruses is both ordered and dynamic, and is believed to be the key for effective transfection. Detailed understanding of the physical properties of viruses, their interaction with cellular components, and responses towards cellular environments leading to transfection would inspire the development of safe and effective non-viral vectors. To this goal, this review systematically summarizes distinctive features of viruses that are implied for efficient nucleic acid delivery but not yet fully explored in current non-viral vectors. The assembly and disassembly of viral structures, presentation of viral ligands, and the subcellular targeting of viruses are emphasized. Moreover, we describe the current development of cationic material-based viral mimicry (CVM) and structural viral mimicry (SVM) in these aspects. In light of the discrepancy, we identify future opportunities for rational design of viral mimics for the efficient delivery of DNA and RNA.


Assuntos
Biomimética/métodos , Terapia Genética/métodos , Vetores Genéticos , Ácidos Nucleicos/administração & dosagem , Transfecção/métodos , Vírus/genética , Animais , Vetores Genéticos/administração & dosagem , Vetores Genéticos/genética , Humanos
2.
Cancer Res ; 69(15): 6184-91, 2009 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-19643734

RESUMO

There is currently no effective therapy for patients with advanced ovarian cancer. To address the need for a more effective treatment for this deadly disease, we conducted preclinical tests in ovarian tumor-bearing mice to evaluate the therapeutic efficacy of using a cationic biodegradable poly(beta-amino ester) polymer as a vector for nanoparticulate delivery of DNA encoding a diphtheria toxin suicide protein (DT-A). The promoter sequences of two genes that are highly active in ovarian tumor cells, MSLN and HE4, were used to target DT-A expression to tumor cells. Administration of DT-A nanoparticles directly to s.c. xenograft tumors and to the peritoneal cavity of mice bearing primary and metastatic ovarian tumors resulted in a significant reduction in tumor mass and a prolonged life span compared to control mice. Minimal nonspecific tissue and blood chemistry toxicity was observed following extended treatment with nanoparticles. DT-A nanoparticle therapy suppressed tumor growth more effectively than treatment with clinically relevant doses of cisplatin and paclitaxel. Our findings suggest that i.p. administration of polymeric nanoparticles to deliver DT-A encoding DNA, combined with transcriptional regulation to target gene expression to ovarian tumor cells, holds promise as an effective therapy for advanced-stage ovarian cancer.


Assuntos
DNA/administração & dosagem , Terapia Genética/métodos , Nanopartículas/administração & dosagem , Neoplasias Ovarianas/terapia , Polímeros/administração & dosagem , Animais , DNA/genética , Proteínas Secretadas pelo Epidídimo/genética , Feminino , Proteínas Ligadas por GPI , Vetores Genéticos/administração & dosagem , Humanos , Glicoproteínas de Membrana/genética , Mesotelina , Camundongos , Nanopartículas/química , Neoplasias Ovarianas/genética , Polímeros/química , Regiões Promotoras Genéticas , Ensaios Antitumorais Modelo de Xenoenxerto , beta-Defensinas
3.
Nat Biotechnol ; 26(5): 561-9, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18438401

RESUMO

The safe and effective delivery of RNA interference (RNAi) therapeutics remains an important challenge for clinical development. The diversity of current delivery materials remains limited, in part because of their slow, multi-step syntheses. Here we describe a new class of lipid-like delivery molecules, termed lipidoids, as delivery agents for RNAi therapeutics. Chemical methods were developed to allow the rapid synthesis of a large library of over 1,200 structurally diverse lipidoids. From this library, we identified lipidoids that facilitate high levels of specific silencing of endogenous gene transcripts when formulated with either double-stranded small interfering RNA (siRNA) or single-stranded antisense 2'-O-methyl (2'-OMe) oligoribonucleotides targeting microRNA (miRNA). The safety and efficacy of lipidoids were evaluated in three animal models: mice, rats and nonhuman primates. The studies reported here suggest that these materials may have broad utility for both local and systemic delivery of RNA therapeutics.


Assuntos
Técnicas de Química Combinatória/métodos , Portadores de Fármacos/química , Desenho de Fármacos , Lipídeos/química , Interferência de RNA , RNA/administração & dosagem , RNA/genética
4.
Mol Ther ; 11(3): 426-34, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15727939

RESUMO

Here we describe the synthesis and characterization of a library of 486 second-generation poly(beta-amino esters). To understand better the structure/property relationships governing polymeric gene delivery, we synthesized polymers with 70 different primary structures, at 6 to 12 different molecular weights, using monomers previously identified as common to effective gene delivery polymers. This library was characterized by (1) molecular weight, (2) particle size upon complexation with DNA, (3) surface charge upon complexation with DNA, (4) optimal polymer/DNA ratio, and (5) transfection efficiency. In this library, polymers with 20 of the 70 primary structures possess transfection efficiencies as good as or better than one of the best commercially available lipid reagents, Lipofectamine 2000. In general, the most effective polymers condense DNA into sub-150-nm complexes with positive surface charge. Among this group, the 2 most effective polymers condensed DNA to the smallest particle sizes (71 and 79 nm). Interestingly, the top 9 polymers were all formed from amino alcohols, and the structure of the 3 top performing polymers differs by only one carbon. This convergence in structure of the top performing polymers suggests a common mode of action and provides a framework with which future polymers can be designed.


Assuntos
Técnicas de Transferência de Genes , Poliaminas , Polímeros , Animais , Células COS , Chlorocebus aethiops , DNA/metabolismo , Ésteres/metabolismo , Nanoestruturas , Poliaminas/metabolismo , Polímeros/metabolismo
5.
Proc Natl Acad Sci U S A ; 101(45): 16028-33, 2004 Nov 09.
Artigo em Inglês | MEDLINE | ID: mdl-15520369

RESUMO

Optimal gene therapy for cancer must (i) deliver DNA to tumor cells with high efficiency, (ii) induce minimal toxicity, and (iii) avoid gene expression in healthy tissues. To this end, we generated a library of >500 degradable, poly(beta-amino esters) for potential use as nonviral DNA vectors. Using high-throughput methods, we screened this library in vitro for transfection efficiency and cytotoxicity. We tested the best performing polymer, C32, in mice for toxicity and DNA delivery after intratumor and i.m. injection. C32 delivered DNA intratumorally approximately 4-fold better than one of the best commercially available reagents, jetPEI (polyethyleneimine), and 26-fold better than naked DNA. Conversely, the highest transfection levels after i.m. administration were achieved with naked DNA, followed by polyethyleneimine; transfection was rarely observed with C32. Additionally, polyethyleneimine induced significant local toxicity after i.m. injection, whereas C32 demonstrated no toxicity. Finally, we used C32 to deliver a DNA construct encoding the A chain of diphtheria toxin (DT-A) to xenografts derived from LNCaP human prostate cancer cells. This construct regulates toxin expression both at the transcriptional level by the use of a chimeric-modified enhancer/promoter sequence of the human prostate-specific antigen gene and by DNA recombination mediated by Flp recombinase. C32 delivery of the A chain of diphtheria toxin DNA to LNCaP xenografts suppressed tumor growth and even caused 40% of tumors to regress in size. Because C32 transfects tumors locally at high levels, transfects healthy muscle poorly, and displays no toxicity, it may provide a vehicle for the local treatment of cancer.


Assuntos
Terapia Genética/métodos , Neoplasias Experimentais/terapia , Polímeros , Animais , Materiais Biocompatíveis , Linhagem Celular Tumoral , DNA Recombinante/administração & dosagem , DNA Recombinante/genética , Toxina Diftérica/genética , Vetores Genéticos , Humanos , Masculino , Teste de Materiais , Camundongos , Camundongos Nus , Proteínas de Neoplasias/biossíntese , Transplante de Neoplasias , Neoplasias Experimentais/metabolismo , Neoplasias Experimentais/patologia , Fragmentos de Peptídeos/genética , Polímeros/síntese química , Polímeros/química , Neoplasias da Próstata/metabolismo , Neoplasias da Próstata/patologia , Neoplasias da Próstata/terapia , Transfecção , Transplante Heterólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA